

COVID-19 VACCINE SCREENING & CONSENT

Clinic Location/Facility Name:	Today's Date (yyyy/mm/dd):			
CLI	ENT INFORMATION			
First Name:	Last Name:			
Date of Year Month Day Age Birth:	☐ Male ☐ Female ☐ Other			
Health Card #	Email:			
Address:	Postal Code: Primary Phone:			
SCR	EENING QUESTIONS			
Have you been diagnosed with myocarditis or pmRNA COVID-19 vaccine?				
Have you been sick in the past few days? Do y fever today?	vou have symptoms of COVID-19 or have a ☐ Yes ☐ No			
Have you had a serious allergic reaction within	4 hours to the COVID19 vaccine before?			
Do you have allergies to polyethylene glycol, tr	romethamine or polysorbate?			
Have you had a serious allergic reaction to a va (e.g., IV, IM), needing medical care?	accine or medication given by an injection Yes No			
Do you have a weakened immune system or a weaken your immune system (e.g., high dose so that it is a system or a weaken your immune system (e.g., high dose so that it is a system or a weaken you receiving stem cell therapy, CAR	steroids, chemotherapy)?			
checkpoint inhibitors, monoclonal antibodies, or other targeted agents?				
Do you have a bleeding disorder or are taking l	blood thinners? Yes No			
Have you ever felt faint or fainted after receivin	g a vaccine or medical procedure?			
Do you have any questions? If yes, please let your immunizer know				
Have you had a previous dose of COVID-19 Vallf yes, Dose 1 date (yyyy/mm/dd) Does 2 date (yyyy/mm/dd)	Product Name: Yes No			
CONSENT & CO	OLLECTION OF INFORMATION			
For individuals receiving a different mRNA vaccine for their second dose following Pfizer BioNTech or Moderna:				
The same mRNA COVID-19 vaccine product should be offered for the second dose in a vaccine series started with an mRNA COVID-19 vaccine if available in the clinic. If the mRNA COVID-19 vaccine used for the first dose is not readily available in the clinic or is unknown, another mRNA COVID-19 vaccine product can be considered interchangeable and should be offered to complete the vaccine series.				
I acknowledge that I have read and understand this information				

For individuals choosing to receive an mRNA vaccine following AstraZeneca COVID-19 vaccine: Individuals who received AstraZeneca for their first dose may choose to receive either AstraZeneca for their second dose or an mRNA vaccine. A dosing interval between eight and 12 weeks is safe and demonstrates a beneficial immune response. There is evidence that a longer interval between two doses of the AstraZeneca vaccine (such as a 12-week interval) provides higher protection				
☐ I acknowledge that I have read and understand this information				
I have read The Regional Municipality of York's (York Region Public Health's) COVID-19 Vaccine Information Sheet or it has been read to me. I understand the benefits and possible side effects of the vaccine and that certain persons listed on the Information Sheet should not get the COVID-19 vaccine. I have had an opportunity to have my questions answered from a representative of the clinic location/facility.				
 I consent to receiving the COVID-19 vaccine, including all recommended doses in the series I understand that I may withdraw this consent at any time. FOR CLIENTS LIVING IN CONGREGATE CARE SETTINGS (example: long-term care homes and retirement homes) I understand that if I am withdrawing consent as a substitute decision maker of an individual, then I must contact the congregate care setting that the individual resides in. 				
Acknowledgement of Collection, Use and Disclosure of Personal Health Information				
The personal health information on this form is being collected for the purpose of providing care to you and creating an immunization record for you, and because it is necessary for the administration of Ontario's COVID-19 vaccination program. This information will be used and disclosed for these purposes, as well as other purposes authorized and required by law. For example, it will be disclosed to the Chief Medical Officer of Health and Ontario public health units where the disclosure is necessary for a purpose of the <i>Health Protection and Promotion Act</i> . It may also be disclosed, as part of your provincial electronic health record, to health care providers who are providing care to you. The information will be stored in a health record system under the custody and control of the Ministry of Health.				
☐ I acknowledge that I have read and understand the above statement.				
You may be contacted for purposes related to the COVID-19 vaccine (for example, to remind you of follow up appointments and to provide you with proof of vaccination).				
☐ I consent to receiving follow-up communications by email or by text/SMS				
Consent to Being Contacted About Research Studies				
You have the option of consenting to be contacted by researchers about participation in COVID-19 vaccine related research studies. If you consent to be contacted, your personal health information will be used to determine which studies may be relevant to you, and your name and contact information will be disclosed to researchers. Consenting to be contacted about research studies does not mean you have consented to participate in the research itself. Participating is voluntary. You may refuse to consent to be contacted about research studies without impacting your eligibility to receive the COVID-19 vaccine. If you consent to be contacted about research studies, and then change your mind, you may withdraw your consent at any time by contacting the Ministry of Health at Vaccine@ontario.ca .				
 ☐ I consent to be contacted about COVID-19 vaccine related research studies: ☐ by email ☐ by text/SMS ☐ by phone ☐ by mail ☐ I do not consent to be contacted about COVID-19 related research studies 				
Client Signature:	Date signed:			
PARENT/LEGAL GUARDIAN/SUBSTITUTE DECISION MAKE Required for children under 12 years of age and others who are unable If applicable: Parent/Legal Guardian/SDM Full Name: If applicable: Parent/Legal Guardian/SDM Signature:	R (SDM) CONSENT - e to provide their own consent Date Signed:			

not entered into COVAX				
Client Full Name:		Client DOB:		
COVID-19 Product Name:	L	_ot #		
Diluent Lot #	Dose volume	: :		
Route and Anatomical Site: IM – Right Deltoid	☐IM – Left	Deltoid		
Date given (yyyy/mm/dd):	Time given:			
Dose Number: One Two Three		ceiving current dose? ☑No		
Reason for Immunization:				
☐ Child/Youth 5+ ☐ Age priority population — Other reason: Age eligible population — ☐ Other reason:				
Reason for Paper Documentation:				
☐ No consent for COVax entry ☐ COVax unav	ailable	Other:		
Immunizer Full Name and Designation:				
Immunizer Signature:				
Complete below if immunization not given				
Reason immunization not given: Immunization is contraindicated HCP decision to temporarily defer immunization Medically ineligible Client withdrew consent HCP recommends immunization but no client consent Below minimum monograph age				
For ACI/office use only to document post-clinic data entry into COVax as appropriate	e entered (office u	Printed Name (office use only)		